exudative age-related macular degeneration
Conditions
Interventions
experimental group:Accurate macular photocoagulation combined with intravitreal injection of anti-VEGF
Sponsors
Hainan Hospital of PLA General Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged >=45 years; 2. The patient was diagnosed as wet-type AMD (including CNV, PCV) in our hospital after relevant examination (slit lamp, fundus photography, Oct, ERG, FFA, ICGA, etc.) and combined with clinical diagnosis; 3. The position of choroidal neovascularization is located 500um outside the center of fovea; 4. The best corrected visual acuity of ETDRS was 0-73 letters; 5. The target eyes were treated with anti VEGF 3 times or more before the experiment, and there was no refractive media turbidity and pupil reduction that affected fundus examination; 6. Sign the informed consent form and be willing to follow up according to the protocol.
Exclusion criteria
Exclusion criteria: 1. Subjects who voluntarily quit; 2. The area of bleeding or exudation in the target eye was more than 6 optic discs; 3. The diameter of scar or fibrosis in the paraocular fovea was more than 500 um; 4. The target eye is associated with other eye diseases (such as RVO, Rao, Dr, DME, CSC, etc.), excluding pathological myopia, cataract and other factors affecting refractive media; 5. There are diseases or conditions in the target eye or the whole body that the researchers think if the subjects continue to participate in this study, they may face greater risks (such as vitrectomy history, grade 3 hypertension, AIDS, malignant tumor, serious mental, cardiovascular, neurological, respiratory, digestive and other system diseases, or long-term hormone use, immune deficiency disease, heart stent surgery, organ poor blood glucose control in diabetic patients; 6. The target eye has undergone intraocular or periocular surgery within 3 months (including laser photocoagulation near the central fovea, cataract surgery, etc.), except for the eyelid surgery which does not affect the vitreous injection (but the eyelid surgery cannot be performed within one month before the administration); 7. The target eye had received corneal transplantation; 9. Cardiovascular events such as stroke, cerebral ischemia and myocardial infarction occurred in the first 6 months; 10. Those who do not use effective contraception; 11. In the course of the study, the researcher decided that it was not suitable to continue to participate in the experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| improvement rate of visual acuity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Macular thickness;Area of choroidal neovascular lesions; | — |
Countries
China
Contacts
Public ContactHuang Houbin
Hainan Hospital of PLA General Hospital
Outcome results
None listed